Form 8-K - Current report:
SEC Accession No. 0001193125-25-073403
Filing Date
2025-04-04
Accepted
2025-04-04 16:06:43
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d876988d8k.htm   iXBRL 8-K 25582
2 EX-99 d876988dex99.htm EX-99 45824
6 GRAPHIC g876988g0404043529016.jpg GRAPHIC 5370
  Complete submission text file 0001193125-25-073403.txt   208417

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20250331.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20250331_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20250331_pre.xml EX-101.PRE 11266
17 EXTRACTED XBRL INSTANCE DOCUMENT d876988d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 25814012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)